There is a paradigm shift happening around us in the clinical care of men with metastatic hormone-sensitive prostate cancer. We now know that survival is better when docetaxel chemotherapy is added to androgen-deprivation therapy (ADT), but there have been and still remains concerns about the toxicity of the docetaxel. Recent findings from a new study, [...]
Clinical trials are used to both demonstrate that a drug or treatment has efficacy (extends life or improves the quality of life). They also are used as the vehicle to obtain approval from the governmental body responsible for monitoring and approving their use. How the trial is set up will directly dictate the eventual approved [...]
Intermittent hormone therapy (IHT) as opposed to continuous hormone therapy (CHT) provides a better quality of life (QoL) for men with locally advanced prostate cancer. However, there is a debate created by a few major research protocols that have been inconclusive as to the difference in achieving the ultimate goal, survival despite prostate cancer. Researchers [...]
Urinary incontinence post-prostatectomy is a too common complaint from men. Although the actual degree of incontinence suffered ranges from being minor, or a simple and small amount of post urination dribble, to a complete and total inability to control any urine flow, the most bothersome issues that significantly affects a man’s quality of life (QoL) [...]
Men who develop bone metastases have often been viewed as having developed a significant negative change that prognosticates a negative impact on both their quality of life and on their survival. Contradicting this commonly held belief has been some research which has identified a subgroup of men with advanced prostate cancer with bone metastases who [...]